Yeon Hee Park, MD, PhD, on Metastatic Breast Cancer: Updated Survival Results of the Young-PEARL Study
2024 ASCO Annual Meeting
Yeon Hee Park, MD, PhD, of South Korea’s Samsung Medical Center and Sungkyunkwan University, discusses phase II findings on palbociclib plus exemestane with a GnRH agonist vs capecitabine in premenopausal patients with hormone receptor–positive, HER2-negative metastatic breast cancer (LBA1002).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
YoungPEARL study is a prospective randomized phase 2 study to compare palbociclib plus exemestane plus GnRH agonist versus capecitabine for premenopausal HR-positive HER2-negative metastatic breast cancers. Actually, this clinical trial was published and presented in 2019. According to that trial research, palbociclib plus exemestane plus GnRH antagonist showed a superior PFS compared to the capecitabine. Their median PFS was 20.1 months versus capecitabine, 14.4 months. This kind of real big research contributed to expansion of palbociclib plus AI label to include premenopausal population.
So now, here we reported updated overall survival research. Data cutoff is February 29th, 2024 with median follow-up duration of 54 months. So we follow up the updated PFS research to show the consistent superior PFS showed in palbociclib arm. Median PFS was 19.5 months versus 14 months of PFS shown in capecitabine arm. Hazard ratio in people was strongly enough to consider it's a big impact in terms of PFS.
And now, we show the overall survival research. There is no big difference between the two arm. Palbociclib arm showed the 54.7 months of PFS, and then capecitabine arm showed a remarkable PFS of 57.8 months. They did not show any difference, but it's 54 months of longer follow-up duration. Palbociclib arm showed a pretty consistent, longer overall survival of 54.8 months. So it's a really... Extended overall survival was shown in palbociclib arm. But palbociclib superior PFS did not lead to the overall survival benefit compare capecitabine arm. But capecitabine arm showed... Multivariate analysis showed the post-treatment CDK4/6 inhibitor was identified as a independent favorable factor for overall survival with statistical significance. So maybe post CDK inhibitor treatment contributed to extended overall survival in palbociclib arm.
The ASCO Post Staff
Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses data reaffirming the efficacy and feasibility of using epcoritamab plus R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin) in autologous stem cell transplant–eligible patients with diffuse large B-cell lymphoma. Response rates were reported to be high, and most patients proceeded to transplant (Abstract 7032).
The ASCO Post Staff
Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).
The ASCO Post Staff
Narjust Florez, MD, of the Dana-Farber Cancer Institute, and Suresh S. Ramalingam, MD, of Emory University School of Medicine, Winship Cancer Institute, discuss potentially practice-changing phase III results from the LAURA study. This trial showed that osimertinib after definitive chemoradiation therapy improved progression-free survival for patients with unresectable stage III EGFR-mutated non–small cell lung cancer (NSCLC), suggesting this agent may represent a new standard of care in this setting (LBA4).
The ASCO Post Staff
Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lenalidomide, and dexamethasone deepened responses and increased the rate of measurable residual disease negativity vs isatuximab with lenalidomide and dexamethasone in patients with newly diagnosed transplant-ineligible multiple myeloma (Abstract 7501).
The ASCO Post Staff
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses up to 5.5 years of follow-up data from the phase II CAPTIVATE study, showing that in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), fixed duration ibrutinib plus venetoclax continues to provide clinically meaningful progression-free disease in those with high-risk genomic features as well as in the overall population (Abstract 7009).